BioLife Solutions, Inc. (NASDAQ:BLFS) has received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation. BioLife Solutions’ rating score has improved by 33.3% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.

Brokers have set a 1 year consensus price objective of $4.25 for the company and are forecasting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given BioLife Solutions an industry rank of 104 out of 265 based on the ratings given to related companies.

Several equities research analysts recently issued reports on the company. Maxim Group reissued a “buy” rating and set a $4.00 price objective on shares of BioLife Solutions in a research note on Wednesday, July 5th. Janney Montgomery Scott upgraded BioLife Solutions from a “neutral” rating to a “buy” rating and raised their price target for the company from $2.62 to $5.00 in a research report on Wednesday, July 5th.

BioLife Solutions (BLFS) opened at 3.40 on Monday. BioLife Solutions has a 12-month low of $1.43 and a 12-month high of $3.74. The firm’s market cap is $44.32 million. The stock’s 50 day moving average price is $2.26 and its 200-day moving average price is $2.01.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 11th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.02. The business had revenue of $2.37 million for the quarter, compared to the consensus estimate of $2.10 million. BioLife Solutions had a negative net margin of 74.58% and a negative return on equity of 74.36%. Equities research analysts anticipate that BioLife Solutions will post ($0.17) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Zacks: BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of “” by Brokerages” was posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/17/zacks-biolife-solutions-inc-nasdaqblfs-given-average-recommendation-of-by-brokerages.html.

About BioLife Solutions

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.